Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The...read more
Deal flow picked up last week with ten IPOs pricing and raising almost $1.9 billion in proceeds. Though it was a strong week for pricings, six of the ten deals slashed...read more
Prosensa, a late-stage biotech developing treatments for Duchenne muscular dystrophy, raised $78 million by offering 6.0 million shares at $13, the high end of the range of $11 to $13. Prosensa plans to list on the NASDAQ under the symbol RNA. Prosensa initially...read more
Three companies priced US IPOs last week, while one was delayed and two, including Votorantim Cimentos (VEBM), the largest expected deal of 2013 year-to-date, were postponed. Two biotechs, bluebird bio (BLUE) and PTC Therapeutics (PTCT), priced upsized...read more
Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues
Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The...read more
US IPO Recap: Market picks up the pace with ten IPOs, six price below the range
Deal flow picked up last week with ten IPOs pricing and raising almost $1.9 billion in proceeds. Though it was a strong week for pricings, six of the ten deals slashed...read more
Prosensa prices IPO at $13, the high end of the range
Prosensa, a late-stage biotech developing treatments for Duchenne muscular dystrophy, raised $78 million by offering 6.0 million shares at $13, the high end of the range of $11 to $13. Prosensa plans to list on the NASDAQ under the symbol RNA. Prosensa initially...read more
US IPO Recap: Biotech success continues, but three deals delayed or postponed
Three companies priced US IPOs last week, while one was delayed and two, including Votorantim Cimentos (VEBM), the largest expected deal of 2013 year-to-date, were postponed. Two biotechs, bluebird bio (BLUE) and PTC Therapeutics (PTCT), priced upsized...read more